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Objectives: There is an urgent clinical need for identifying blood-based diagnostic biomarkers 
for Dementia with Lewy Bodies (DLB). Transcriptomic studies have reported unique RNA 
changes in post-mortem DLB brains. Small extracellular vesicles (SEV) that transport RNA 
between brain and peripheral circulation enable identifying molecular changes in living human 
brain. Hence, we aimed to identify differentially expressed RNA in serum SEVs from people 
with DLB. 
Methods: We investigated serum SEV total RNA profiles in people with DLB (n=10) and age 
and gender matched comparisons (n=10) using next-generation RNA-sequencing. SEVs were 
separated by ultracentrifugation with density gradient and were characterized by nanoparticle 
analysis and western blotting. We verified identified differentially expressed genes (DEG) 
using high-throughput qPCR. Functional implications of identified DEG were evaluated using 
Ingenuity pathway analyses.  
Results: We identified 846 nominally significant DEG including 30 miRNAs in DLB serum 
SEVs. We identified significant downregulation of pro-inflammatory genes, IL1B, CXCL8 and 
IKBKB. Previously reported post-mortem DLB brain DEGs were significantly enriched 
(χ2=4.99; df=1; p=0.03) among the identified DEGs, and the differential expression of 40 post-
mortem DLB brain DEGs could be detected in serum SEVs of people living with DLB. 
Functional pathway and network analyses highlighted the importance of immunosenescence, 
ubiquitin proteasome system (UPS) dysfunction, DNA repair and RNA post-transcriptional 
modification deficits in DLB pathology. 
Conclusion: Identified DEGs, especially reduced expression levels of inflammation and UPS 
associated RNA, may aid diagnosing DLB, and their biomarker potential warrants further 
investigation in larger clinical cohorts. Our findings corroborate the absence of chronic 




 Dementia with Lewy bodies (DLB) is the second most common neurodegenerative 
dementia (1) that causes earlier mortality (2), earlier nursing home admissions, higher costs (3) 
and more caregivers’ burden than Alzheimer’s disease (AD). DLB (4) and AD are diagnosed 
by their clinical diagnostic criteria. Currently, the three available indicative diagnostic 
biomarkers (4) for DLB are not routinely used in clinical settings (5), and there is no reliable 
biological fluid based biomarker for aiding DLB diagnosis. Failure to diagnose DLB accurately 
and treating visual hallucinations and challenging behaviors, more frequent in DLB than in 
AD, with any antipsychotic medication can lead to potentially fatal adverse effects including 
neuroleptic malignant syndrome (5). Moreover, early diagnosis of DLB is essential for 
formulating appropriate multidisciplinary management plans. Hence, there is an urgent clinical 
need for identifying reliable blood-based diagnostic biomarkers for DLB, but pertinent research 
remains sparse (6). 
 Better understanding of molecular pathology of DLB is important for identifying 
reliable biomarkers. Two genome-wide association studies (7,8) and at least 73 candidate gene 
association studies have investigated the molecular genetics of DLB so far (9). Genetic 
associations between DLB and variants in APOE, GBA, SNCA and MAPT have been replicated 
by two or more studies. Other reported genetic associations of DLB that need further replication 
include the variants in BCHE-K, BCL7C, CHRFAM7A, CNTN1, GABRB3, mtDNA, NOS2A, 
PSEN1, SCARB2, TREM2, ZFPM1 and UCHL1 (9). Gene expression studies investigating 
RNA levels clarify functional implications of identified genetic associations and their 
dysfunctional molecular networks. RNA changes indicate the effects of gene-environment 
interactions, and the changes in non-coding RNA levels add functional information that cannot 
be provided by studies investigating DNA and proteins. Three next-generation RNA 
sequencing (RNA-Seq) studies (10), and at least 21 quantitative gene expression studies have 
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investigated gene expression changes in people with DLB (11). Most of them have studied 
gene expression changes in post-mortem DLB brains and they have reported 4,842 statistically 
significant differentially expressed genes (DEG) in post-mortem DLB brains (10). We have 
previously reported DEGs, identified by RNA-Seq, and metabolic reprogramming in post-
mortem anterior cingulate and dorsolateral prefrontal cortices of pathology-verified DLB 
(10,11). We identified four genome-wide statistically significant DEGs (CTSG, SELE, GIPR 
and PSPHP1), and have documented significant downregulation of several pro-inflammatory 
genes in post-mortem DLB brains (10). Although prior evidence have confirmed unique RNA 
expression changes in post-mortem DLB brains (11), identifying differentially expressed RNA 
in biological fluids such as blood or cerebrospinal fluid (CSF) of people living with DLB is 
necessary for discovering novel clinically applicable diagnostic biomarkers. Yet, studies 
investigating RNA levels in biological fluids of people with DLB are sparse (11). One study 
has reported significant downregulation of miR-125b in DLB CSF (12) and another two studies 
that investigated peripheral leukocytes (13,14) have reported significant upregulation of SNCA-
126 isoform and significant downregulation of four mitochondrial genes, ATP8, MT-CO2, MT-
CO3 and MT-ND2, in DLB. 
 Each neurodegenerative disorder is hypothesized to have its own unique peripheral 
RNA signature (15). The discovery of small (30-100nm) extracellular vesicles (SEV) that can 
cross the blood-brain barrier and can transport RNA between brain and peripheral circulation  
has opened up an avenue for studying molecular changes in living human brain by investigating 
peripheral blood samples (16). Studies investigating extracellular vesicles (EV) have been 
increasing exponentially since the last decade, and the minimal information for studies of 
extracellular vesicles (MISEV2018) guidelines was published by the International Society of 
Extracellular Vesicles in 2018 (17). The MISEV2018 guidelines discourage using the 
previously popular term “exosomes” that assumed specific biogenesis, and they urge naming 
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EVs based on their physical or biochemical characteristics (17). Nearly 100 EV-based 
diagnostic and prognostic biomarkers have been identified for various malignancies (18). The 
diagnostic biomarker potential of serum or plasma SEVs for neurodegenerative disorders is 
increasingly recognized (19), and several potential diagnostic SEV RNA biomarkers for AD 
have been identified (20). Moreover, CSF derived SEVs from people with DLB can induce α-
synuclein aggregation in-vitro (21). However, only one study has investigated CSF, serum, or 
plasma SEV RNA profiles of people with DLB so far (22). That exploratory study has 
sequenced only microRNA (miRNA) profiles of plasma SEV RNA from seven people with 
DLB, and it could not identify any statistically significant differentially expressed miRNA 
between DLB and comparisons (22). SEV long RNA including messenger RNA (mRNA) 
profiles in DLB have not been investigated so far. Hence, we aimed to conduct a RNA-Seq 
study investigating serum SEV total RNA profiles of people living with DLB. 
 
Methods:  
Serum samples:  
 We obtained serum samples from the biobanks of three Norwegian cohorts (23-25). 
The dementia study of western Norway (DemWest) is a relatively large longitudinal cohort 
study (23) including people with probable DLB (26). The DLB diagnosis was based on a 
standardized set of clinical and biomarker analyses, longitudinal follow-up, and pathological 
confirmation of a subset (27). Serum samples from 10 people living with probable DLB, and 
three gender and age (±3 years) matched comparisons without cognitive impairment or 
Parkinson’s disease (NDC; No-dementia comparison) were obtained from this cohort. Another 
seven gender and age (±3 years) matched NDC serum samples were obtained from two cohorts 
at Akershus University Hospital dementia research centers (24,25). All three cohorts allowed 
30 minutes for coagulation of their blood samples, centrifuged their samples at room 
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temperature and stored them at -80°C until use. There were minor variations in the duration 
and speed of their centrifugation procedures. Supplemental digital content (SDC-1) provides 
age, gender, cohort, and centrifugation details of all 20 samples. The data on the Mini-mental 
status examination total score (28), the Clinical Dementia Rating Scale global score, and the 
number of years of formal education were available only for the DemWest cohort samples, and 
they are presented in the SDC-1. Further details of the cohorts have been published elsewhere 
(23-25). These studies have obtained generic ethical approval for further studies using their 
serum samples.  
Separation of EVs:  
 SEVs were separated using an ultracentrifugation and OptiPrepTM (Sigma-Aldrich, UK) 
density gradient approach based on their buoyant density. In brief, a discontinuous iodixanol 
gradient was prepared by diluting a stock solution of OptiPrepTM (60%w/v) with 0.25M 
sucrose/10 mM Tris (pH 7.5) for generating 40%, 20%, 10% and 5%w/v iodixanol solutions. 
The solutions were sequentially layered (3 ml/layer) in an UltraClear (Beckman Coulter, USA) 
centrifuge tube, and 0.5ml of serum/ sample was overlaid. The tubes were centrifuged at 
100,000g at 4°C for 16 hours. Subsequently, 12 fractions of one ml were collected from the 
top of the gradient. Ninth to 11th fractions were diluted in phosphate buffered saline (PBS) (29). 
They were centrifuged further at 100,000g for one hour at 4°C in an Optima-Max centrifuge 
(Beckman Coulter, USA), and this was repeated once more. After discarding the supernatant, 
the SEV pellet was reconstituted with 200µl PBS.  
Characterization of EVs:  
Size distribution and concentration of separated EVs were verified using the Malvern 
NanoSight LM10 nanoparticle analyzer (Malvern Instruments Ltd., UK) using standard 
manufacturer’s instructions. Separation of SEVs was confirmed by Western blotting using 
antibodies against Flotillin-1 and CD63, which are widely used exosomal markers (17). 
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RNA extraction:  
 Total SEV RNA including all mRNA, miRNA, and other small RNA were purified 
using the Invitrogen total exosome RNA isolation kit (Thermo Fisher Scientific, USA). Quality 
of purified RNA were assessed using the NanoDrop™ One/One microvolume UV-Vis 
spectrophotometer (Thermo Fisher Scientific, USA), and the mean 260/280 absorbance ratio 
of purified RNA was 2.05 (95%CI 1.88-2.22).  
Next-generation RNA-sequencing (RNA-Seq):  
 Purified serum SEV RNA were sequenced at the Wellcome Centre for Human Genetics, 
Oxford, UK, using the Illumina HiSeq-2500 (Illumina, USA).  A NEBNext Ultra-II directional 
cDNA library and another NEBNext small RNA cDNA library (New England Biolabs, USA) 
were prepared for each sample. The cDNA libraries underwent single-end sequencing (50 base 
pairs/read), and we obtained a minimum of 10 million reads/sample. 
RNA-Seq data analyses:  
 Quality control of RNA-Seq reads removed the reads that included an ambiguous base, 
and the reads that had less than 90% of bases with less than 1% sequencing error. Remaining 
reads were aligned to the human genome (Homo_sapiens.GRCh38) with corresponding gene 
model annotation (Homo_sapiens.GRCh38.88.gtf) using the HISAT2 (30). Gene-wise counting 
of aligned reads was completed using the featureCounts tool (31). DEGs in DLB serum SEVs 
were identified by a previously experimentally validated (32) edgeR 3.18.1 algorithm 
employing generalized linear models with tag-wise dispersion (33), and Benjamini-Hochberg 
transcriptome-wide false discovery rate (FDR) correction (5%). The edgeR p-values were 
derived by employing exact tests (no df) after fitting gene-specific quasi-negative binominal 





Verification of identified DEGs:  
 Differential expression levels of 48 identified DEGs (SDC-2) in serum SEVs of people 
living with DLB were evaluated using high-throughput quantitative polymerase chain reactions 
(qPCR). Total SEV RNA were purified using the Invitrogen total SEV RNA isolation kit 
(Thermo Fisher Scientific, USA) from 0.5ml aliquots of serum samples that had been 
sequenced (N=20). 100ng of SEV RNA/sample were reverse transcribed using the miScript®-
II RT Kit and its 5X miScript HiFlex buffer (Qiagen, UK). After 19 cycles of specific target 
amplification with the PreAmp master-mix (Fluidigm, USA), high-throughput qPCR was 
performed using the BioMark HD, GE 96.96 dynamic arrays (Fluidigm, USA), and SsoFast 
EvaGreen low ROX kit (Bio-Rad, USA). SDC-3 provides further details of the qPCR 
verification. A DEG would be verified if it met the following criteria (34): (i) Both RNA-Seq 
and qPCR showed same direction of differential expression, and (ii) differential expression 
fold change, estimated by qPCR, was either above 1.25 or below 0.80 (logarithmic fold change 
(L2FC) cut-off ±0.3219). 
Functional analyses of identified DEGs: 
 Functional implications of identified DEGs (edgeR p<0.05; no df) were analyzed by 
Ingenuity Pathway Analysis (IPA) using the Ingenuity knowledge base (Ingenuity, USA). The 
IPA is a powerful functional analysis tool that helps identifying potential biomarkers within 
the context of biological systems. Our IPA analysis settings included stringent filters with only 
experimentally observed relationships, and they helped identifying disrupted functional 
pathways and dysfunctional molecular networks in serum SEVs of people with DLB. The IPA 
p-values were calculated by estimating the ratio of the number of DEGs that map to a canonical 
pathway to the total number of molecules that map to that canonical pathway, and then by using 
Fisher’s exact test (no df) for determining the probability that the association between the 




Serum SEV RNA profile: 
 The Malvern NanoSight LM10 nanoparticle analysis revealed that 94.47% (95%CI 
92.13-96.81%) of the separated EVs were between 30 and 100nm in size. Mean amount of total 
purified SEV RNA/ sample, estimated by the NanoDrop™ One/One microvolume UV-Vis 
spectrophotometer (Thermo Fisher Scientific, USA), was 227.80 (95%CI 149.39-306.21) ng. 
All RNA-Seq data files are available in the NCBI BioProject database under accession number 
PRJNA530121 (https://www.ncbi.nlm.nih.gov/sra/PRJNA530121). RNA, expressed from 429 
miRNA genes and 8,863 other genes, were found in the investigated serum SEVs. Only 244 
(56.9%) miRNA genes and 3,314 (37.4%) other genes were expressed in both DLB and NDC 
serum SEVs. RNA, expressed from 28 mitochondrial genes, were found in both DLB and NDC 
serum SEVs. 112 (26.1%) miRNA genes and 2,173 (24.5%) other genes were expressed only 
in DLB serum SEVs.  
Serum SEV DEGs in DLB:  
 We identified 846 statistically significant (edgeR p<0.05; no df) DEGs in serum SEVs 
of people with DLB, compared to NDC serum SEVs (SDC-4). There were 737 downregulated 
and 109 upregulated DEGs. They included 30 differentially expressed miRNA and one 
mitochondrial gene, MT-TS2, encoded RNA. None of the DEGs reached transcriptome-wide 
statistical significance (edgeR q<0.05; no df) after Benjamini-Hochberg FDR correction. 
However, differential expression levels of 77.1% (37/48; 95%CI 65.2-89.0%) of the nominally 
significant DEGs (edgeR p<0.05; no df) could be verified (34) by high-throughput qPCR, and 
Table-1 presents those 37 qPCR verified DEGs. RNA expression levels of pro-inflammatory 
genes, IL1B, CXCL8 and IKBKB were significantly (edgeR p<0.05; no df) downregulated in 
DLB serum SEVs, and their differential expression were also verified by qPCR. Other 
statistically significant (edgeR p<0.05; no df) downregulated DEGs in DLB, verified by qPCR, 
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included pro-apoptotic BID and TNFRSF1A, ubiquitin proteasome system (UPS) associated 
UBE3A, USP47, and PSMD4, as well as PSEN1 regulating β-amyloid synthesis. Moreover, 
qPCR-verified significantly (edgeR p<0.05; no df) upregulated DEGs in DLB serum SEVs 
included PTPRF, MIR556, and SMG9 that plays a critical role in the nonsense-mediated mRNA 
decay (NMD). PTPRF encodes a protein tyrosine phosphatase that contributes to the regulation 
of cell growth, differentiation, mitotic cycle, insulin resistance and oncogenesis (36). MIR556 
has been reported to be associated with the proliferation and migration of various malignancies 
(37). SDC-5 presents the z-scores of edgeR normalized expression levels of the 37 qPCR 
verified DEGs. z-scores above two in at least one of the following three genes, SMG9, PTPRF, 
and MIR556, could classify the people with DLB with 60% sensitivity, 100% specificity, 100% 
positive predictive value, and 71.43% negative predictive value. 
Comparing with DEGs in post-mortem DLB brains: 
 We cross-linked our post-mortem cortical transcriptomic data that have been reported 
elsewhere (10) with the DLB serum SEV RNA profiles, and found statistically significant 
(χ2=4.99; df=1; p=0.03) enrichment of post-mortem DLB brain DEGs (edgeR p<0.05; no df) 
among the DEGs (edgeR p<0.05; no df) identified in this study. Table-2 presents the 40 DEGs 
that were differentially expressed in both post-mortem DLB brains and serum SEVs of people 
living with DLB. Expression levels of pro-inflammatory genes, IL1B, CXCL8 and IFI44L were 
significantly (edgeR p<0.05; no df) downregulated in both post-mortem DLB brains and DLB 
serum SEVs. In addition, ABCA13, involved in active transmembrane transport of lipid species, 
PARVB, involved in GTPase activation and integrin signaling, and a transcriptional activator 
LBH were significantly (edgeR p<0.05; no df) downregulated in both datasets. Moreover, 
JUND that antagonizes apoptosis and slows down cell growth as well as AVP encoding 
vasopressin, neurophysin 2 and copeptin were significantly (edgeR p<0.05; no df) upregulated 
in both post-mortem DLB brains and DLB serum SEVs. 
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Functional analyses of identified DEGs: 
 We investigated the functional implications of the 846 identified DEGs (edgeR p<0.05; 
no df) using  IPA. SDC-6 presents the molecular pathways that were significantly enriched 
among the serum SEV DEGs in people with DLB. Huntington's disease signaling (Fisher’s 
exact p=3.05X10-5; no df), regulation of eIF4 and p70S6K signaling (Fisher’s exact 
p=4.21X10-5; no df), and glucocorticoid receptor signaling (Fisher’s exact p=5.96X10-5; no df) 
associated genes were significantly enriched among the identified DEGs. Pro-inflammatory 
pathways such as role of PKR in interferon induction and antiviral response (Fisher’s exact 
p=1.89X10-4; no df), TNFR1 signaling (Fisher’s exact p=6.65X10-4; no df), IL-6 signaling 
(Fisher’s exact p=6.88X10-4; no df), IL-8 signaling (Fisher’s exact p=0.001; no df), interferon 
signaling (Fisher’s exact p=0.004; no df) and T-cell receptor signaling (Fisher’s exact p=0.01; 
no df) were significantly downregulated in DLB serum SEVs. Integrin signaling (Fisher’s exact 
p=3.44X10-4; no df) and Integrin linked kinase signaling (Fisher’s exact p=3.27X10-4; no df) 
pathways were significantly enriched among the identified DEGs, and the overlapping DEGs 
were predominantly downregulated in DLB serum SEVs. Moreover, protein ubiquitination 
pathway was significantly (Fisher’s exact p=0.007; no df) enriched among the identified DEGs, 
and 15 identified significantly (edgeR p<0.05; no df) downregulated DEGs overlapped with 
this pathway. Furthermore, IPA upstream and causal network analyses indicated that 
downregulation of transcription regulators, TP53 (Fisher’s exact p=1.38X10-7; no df), NUPR1 
(Fisher’s exact p=2.72X10-4; no df) and WT1 (Fisher’s exact p=4.32X10-4; no df) and of 
TYROBP (Fisher’s exact p=5.65X10-4; no df) encoding a transmembrane receptor were 
probable upstream causes that may explain the identified DEGs in DLB serum SEVs.  
The network analyses showed that the direct and indirect interactions of several 
identified DEGs converge on the following three downregulated DEGs that interact among 
themselves, (i) IL1B encoding Interleukin-1β, (ii) pro-apoptotic CASP3, and (iii) PSEN1 that 
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is essential for γ-secretase complex cleaving β-amyloid from amyloid precursor protein (APP) 
(Figure-1A). This dysfunctional molecular network can explain how the interactions between 
the DEGs may impact neuronal survival, organismal injury, and apoptosis in DLB. Moreover, 
several identified DEGs and their interactions can influence transcriptional regulation of many 




 This is the first study that systematically investigated serum SEV total RNA profiles of 
people living with DLB and their overlap with post-mortem DLB cortical transcriptomic data. 
The study has confirmed the feasibility of measuring gene expression changes in serum SEVs 
of people living with DLB like measuring such changes in post-mortem DLB brains. It has 
identified differentially expressed mRNA and miRNA, and their dysfunctional molecular 
networks in serum SEVs from people with DLB. We have observed that previously reported 
post-mortem DLB brain DEGs (10) were significantly enriched among the DEGs identified by 
this study, and that the statistically significant differential expression of 40 post-mortem DLB 
brain DEGs (10) could be detected in serum SEVs of people living with DLB. Our findings 
have highlighted the importance of immunosenescence, UPS dysfunction, and the deficits in 
DNA repair, RNA post-transcriptional modification, and APP processing in DLB pathology.  
 Chronic microglial activation and neuroinflammation contribute to AD pathology (38). 
However, prior evidence supporting chronic neuroinflammation in DLB have been 
inconsistent, and several immunohistochemical, transcriptomic and proteomic studies have 
documented notable absence of chronic neuroinflammation in post-mortem DLB brains 
(9,11,39). Transcriptomic studies using gene expression microarray and RNA-Seq 
methodologies have reported statistically significant downregulation of several pro-
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inflammatory genes including IL1B, IL2, IL6, CXCL2, CXCL3, CXCL8, CXCL10, and CXCL11 
in post-mortem DLB brains (10,40). Another transcriptomic and proteomic study corroborated 
the absence of chronic neuroinflammation in post-mortem pulvinar region of DLB brains (41). 
Moreover, immunohistochemical staining with IBA1 and CD68 antibodies revealed reduced 
microglial density and more microglial dystrophy in post-mortem DLB brains (42). In this 
study, we have observed statistically significant reduced expression of pro-inflammatory 
genes, IL1B, CXCL8, IFI44L and IKBKB, and statistically significant downregulation of 
several inflammatory pathways, such as TNFR1, IL-6, IL-8, interferon and T-cell receptor 
signaling pathways in DLB serum SEVs. Neuronal survival and synaptic plasticity require 
optimal microglial activation (43), and immunosenescence leading to impaired neuronal 
survival may contribute more to DLB pathology than chronic neuroinflammation (10,11). 
Hence, reduced expression levels of the identified pro-inflammatory DEGs in serum SEVs may 
aid diagnosing DLB early and may help distinguishing DLB from AD. Their diagnostic and 
prognostic biomarker potential needs to be investigated in larger clinical cohorts. 
 The UPS is an important intracellular degradation system for clearing pathologically 
misfolded proteins, and its dysfunction substantially contributes to the progression of α-
synucleinopathies (44). Our findings revealed significantly reduced levels of UPS associated 
genes, UBE3A, USP47, and PSMD4, and significant downregulation of the protein 
ubiquitination pathway in DLB serum SEVs. An earlier study that investigated RNA profiles 
of substantia nigra dopaminergic neurons of people with Parkinson’s disease has reported 
statistically significant downregulation of USP47 and PSMD4 (45). The UPS closely interacts 
with the autophagy lysosomal pathway, and its dysfunction has been demonstrated to be 
sufficient for inducing Lewy body-like inclusions in mice models (46). Downregulation of the 
protein ubiquitination pathway aggravates α-synuclein aggregation and cytoplasmic 
accumulation of other misfolded proteins that can set off a vicious cycle by inhibiting the 
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neuronal autophagy lysosomal pathway. However, systematic research investigating the 
diagnostic biomarker and therapeutic potential of the UPS molecules in DLB remain sparse. 
Significant downregulation of UBE3A, USP47, and PSMD4 in serum SEVs in people with 
DLB could be detected by both RNA-Seq and qPCR, and their diagnostic biomarker potential 
warrants further research. 
 α- synuclein is a DNA binding protein and it regulates DNA damage response and DNA 
repair (47). DNA repair deficits and consequent increased levels of DNA double strand breaks 
are associated with Lewy body pathology and neurodegeneration in mice models and post-
mortem human DLB brains (47). Moreover, transcriptional RNA processing such as RNA 
splicing contributes to α-synuclein aggregation (48). We have presented a dysfunctional 
molecular network involving several identified DEGs that can affect DNA repair and RNA 
post-transcriptional modification. Downregulation of RPA1 that plays an important role in 
DNA replication, and downregulation of CUL4A, an ubiquitin ligase protein that regulates 
DNA repair, can impair neuronal survival by affecting DNA damage response in DLB. CUL4A, 
and RNMT that catalyzes mRNA cap methylation interact with RNA polymerase II (49) and 
their downregulation may lead to reduced expression of many downstream genes that are 
essential for neuronal survival in DLB. As SEVs deliver RNA to recipient cells and modify 
DNA damage response in recipient cells (50), this dysfunctional molecular network may 
contribute to the progression of DLB pathology.  
Downregulation of PSEN1 can increase α-synuclein aggregation independent of its γ-
secretase activity, and it may explain varying degrees of comorbid AD pathology in DLB (51). 
Besides, significantly reduced expression levels of pro-apoptotic CASP3 and BID in DLB 
serum SEVs are intriguing. Apoptosis and mitosis maintain tissue homeostasis, and decreased 
apoptosis may pathologically prolong survival of dysfunctional cells (52). The cell cycle two-
hit hypothesis that involves non-dividing neurons re-entering into steady state G1 phase, and 
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then losing their ability to undergo apoptosis because of chronic oxidative stress has been 
studied extensively in AD (53). Although α- synuclein is known to alter cell cycle progression 
(54), the contributions of cell cycle re-entry and decreased apoptosis towards DLB pathology 
have not been investigated. Molecular mechanisms underlying reduced expression of CASP3 
in DLB serum SEVs and its impact on autophagy lysosomal pathway in recipient cells (55) 
warrant further investigation. Moreover, ATP-binding cassette family genes, ABCA7 and 
ABCA13, were significantly downregulated in DLB serum SEVs. Rare variants in ABCA13 
have been associated with various neuropsychiatric disorders (56), and common variants in 
ABCA7 have been associated with AD (57). Future studies may consider investigating their 
contributions towards the molecular pathology of DLB. 
We acknowledge the limitations of this study including its small sample size and 
investigating the total serum SEV population that was not enriched for neuronal origin. Further 
studies should compare DLB SEV RNA profiles with those of people with AD for 
disentangling disease-specific effects. However, circulating SEV RNA have opened a new 
avenue for identifying blood-based diagnostic biomarkers for DLB, and diagnostic biomarker 
potential of identified DEGs warrant further evaluation in large replication cohorts. 
Multiplexing biomarkers improves their diagnostic accuracy and predictive values, and 
potential RNA biomarkers can be investigated together by developing a multiplex RNA 
biomarker assay (58). The diagnostic accuracy including sensitivity and specificity of such 
biomarker assay will need further investigation. Moreover, gene expression changes are 
dynamic, and they differ with disease progression. Measuring the expression levels of 
identified DEGs at various clinical stages of DLB may help diagnosing DLB early, identifying 
novel prognostic biomarkers, and advancing our understanding of molecular pathology of 
rapidly progressive DLB (59). Furthermore, investigating SEVs that are enriched for neuronal 
origin by L1CAM immunoprecipitation can enhance study power and biomarker discovery 
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(19). However, the caveat is that only 5-10% of circulating SEVs are considered to be of 
neuronal origin (19), and limited starting volumes of clinical blood samples make the 
investigation of neuronally enriched serum or plasma SEV RNA profiles methodologically 
challenging. Several methodological challenges have been identified in separation, enrichment, 
quantification, characterization, and functional analysis of EVs, and the MISEV2018 
guidelines have made specific recommendations for improving methodologies of further 
research in this important area (17). Optimizing the immunoprecipitation and RNA-Seq library 
preparation methods for investigating very low input neuronally enriched SEV RNA will aid 




















Figure-1: Functional network analyses of identified differentially expressed genes in serum 
small extracellular vesicles of people living with dementia with Lewy bodies. 
A: A network of 32 identified DEGs that may impact cell death and survival, and organismal 
injury and abnormalities; B: Another network of identified DEGs that can influence gene 
expression, RNA post-transcriptional modifications, DNA replication, recombination, and 
repair; (A-B) Green represents downregulated genes, and red represents upregulated genes. 




















Supplemental Digital Content (SDC): 
Note: Supplementary information are available in the online version of the paper. 
1. SDC-1 presents the sample characteristics (.docx file). 
2. SDC-2 presents forward and reverse primer sequences that have been used for high-
throughput qPCR verification of 48 identified differentially expressed genes (DEG) (first 
worksheet) and eight reference (second worksheet) genes (.xlsx file).  
3. SDC-3 presents an overview of separation of small extracellular vesicles, RNA extraction, 
cDNA synthesis, specific target amplification and high-throughput qPCR verification 
procedures (.docx file). 
4. SDC-4 presents differential expression analyses of RNA-Seq data from serum small 
extracellular vesicles of people living with dementia with Lewy bodies (n=10) and of age 
and gender matched comparisons without cognitive impairment or Parkinson’s disease 
(n=10) (.xlsx file). 
5. SDC-5 presents the Z-scores of edgeR normalized expression levels of the 37 qPCR 
verified DEGs 
6. SDC-6 presents the results of Ingenuity pathway analyses that identified the canonical 
pathways, which were statistically significantly enriched among the identified DEG in 
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